secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0000950170-24-134969
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences discontinues tildacerfont CAH program after Phase 2b miss
----------------------------------------------------------------------------

- Phase 2b CAHmelia-204 missed primary endpoint: placebo-adjusted GC dose reduction of 0.7mg HCe (p=0.7).
- 98% compliance; no serious adverse events reported in CAHmelia-204.
- Phase 2 CAHptain-205 showed trend of larger A4 reductions at higher BID doses; no drug-related SAEs.
- Company discontinuing both trials, winding down tildacerfont investment, and evaluating strategic options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024134969/0000950170-24-134969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024134969/sprb-20241210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-134969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer